Chemokine Therapeutics Receives Approval From Hong Kong to Commence Phase II Study in Liver Cancer
Chemokine Therapeutics Corp. announced that it has received a Certificate for Clinical Trial/Medicinal Test from the Hong Kong Department of Health allowing the Company to begin a Phase II trial in liver cancer with its lead drug candidate, CTCE-9908. The Company received FDA and Health Canada approval for the clinical trial earlier this year.
The Phase II trial will be an international, multi-centre, randomized, controlled, open label study assessing the efficacy and safety of CTCE-9908 that will include up to 132 patients with liver cancer.
"Liver cancer is more prevalent in the Asian communities and working with Dr. Ronnie Poon, Principal Investigator for Hong Kong, will help to expedite the patient recruitment process," stated Walter Korz, President and Chief Executive Officer of the Company.
Most read news
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.